Asthika Goonewardene Analyst Performance

Managing Director, Senior Biotech Analyst at Truist Financial

Asthika Goonewardene is a stock analyst at Truist Financial in the medical sector, covering 12 publicly traded companies. Over the past year, Asthika Goonewardene has issued 17 stock ratings, including buy and hold recommendations. While full access to Asthika Goonewardene's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Asthika Goonewardene's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 21 Last 5 Years
Buy Recommendations: 85.71% 18 Buy Ratings
Companies Covered: 12 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	85.7%	18 ratings
Hold	14.3%	3 ratings
Sell	0.0%	0 ratings

Out of 21 total stock ratings issued by Asthika Goonewardene at Truist Financial, the majority (85.7%) have been Buy recommendations, followed by 14.3% Hold.

Best & Worst Calls

Best Call
000.0%
EXEL
Jul 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
CELU
Oct 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	12 companies

Asthika Goonewardene, an analyst at Truist Financial, currently covers 12 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 12 companies	100.0%

Asthika Goonewardene of Truist Financial specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 12 companies	100.0%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
JANX Janux Therapeutics	9/10/2025	Initiated Coverage	$23.78	$100.00	Buy
RVMD Revolution Medicines	9/5/2025	Initiated Coverage	$38.95	$99.00	Buy
MRSN Mersana Therapeutics	8/14/2025	Lower Price Target	$7.65	$36.00	Buy
GILD Gilead Sciences	8/8/2025	Upgrade	$110.28	$127.00	Buy
EXEL Exelixis	7/29/2025	Lower Price Target	$37.22	$49.00	Buy
EXEL Exelixis	7/15/2025	Boost Price Target	$44.47	$56.00	Buy
GMAB Genmab A/S	7/8/2025	Boost Price Target	$21.33	$46.00	Buy
EXEL Exelixis	6/23/2025	Reiterated Rating	$43.61	$55.00	Buy
BNTX BioNTech	6/3/2025	Reiterated Rating	$116.20	$155.00	Buy
MRSN Mersana Therapeutics	5/16/2025	Boost Price Target	$8.33	$250.00	Buy
LEGN Legend Biotech	5/14/2025	Lower Price Target	$28.41	$71.00	Buy
ALLO Allogene Therapeutics	5/14/2025	Lower Price Target	$0.93	$10.00	Buy
GMAB Genmab A/S	3/11/2025	Lower Price Target	$20.25	$45.00	Buy
IOVA Iovance Biotherapeutics	3/3/2025	Lower Price Target	$4.09	$15.00	Buy
CRGX CARGO Therapeutics	1/30/2025	Downgrade	$13.19	$7.00	Hold
EXEL Exelixis	1/27/2025	Boost Price Target	$32.99	$43.00	Buy
EXEL Exelixis	1/15/2025	Boost Price Target	$36.78	$42.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.